Amneal Pharmaceuticals (AMRX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Amneal Pharmaceuticals (AMRX)
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Key Insights
Critical company metrics and information
Share Price
$8.45Market Cap
$2.62 BillionTotal Outstanding Shares
309.84 Million SharesTotal Employees
7,700Dividend
No dividendIPO Date
May 7, 2018SIC Description
Pharmaceutical PreparationsHomepage
https://www.amneal.com
Historical Stock Splits
If you bought 1 share of AMRX before August 26, 2013, you'd have 0.04 shares today.
Execution Date | Split Amount |
---|---|
August 26, 2013 | 1-for-25 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities, Continuing | $-251.42 Million |
Net Cash Flow From Operating Activities, Continuing | $312.84 Million |
Net Cash Flow From Investing Activities, Continuing | $-78.63 Million |
Exchange Gains/Losses | $58000.00 |
Net Cash Flow, Continuing | $-17.20 Million |
Net Cash Flow From Investing Activities | $-78.63 Million |
Net Cash Flow From Financing Activities | $-251.42 Million |
Net Cash Flow | $-17.26 Million |
Net Cash Flow From Operating Activities | $312.84 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Basic Earnings Per Share | $0.86 |
Diluted Earnings Per Share | $0.85 |
Other Operating Expenses | $120.38 Million |
Net Income/Loss Attributable To Parent | $-179.73 Million |
Selling, General, and Administrative Expenses | $456.75 Million |
Net Income/Loss | $-146.48 Million |
Preferred Stock Dividends And Other Adjustments | $4.73 Million |
Income/Loss From Continuing Operations After Tax | $-146.48 Million |
Benefits Costs and Expenses | $2.80 Billion |
Nonoperating Income/Loss | $-310.88 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $37.98 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $4.73 Million |
Cost Of Revenue | $1.73 Billion |
Costs And Expenses | $2.80 Billion |
Income/Loss From Continuing Operations Before Tax | $-123.16 Million |
Revenues | $2.68 Billion |
Operating Expenses | $759.67 Million |
Basic Average Shares | $640.62 Million |
Diluted Average Shares | $637.70 Million |
Gross Profit | $947.39 Million |
Research and Development | $182.53 Million |
Operating Income/Loss | $187.73 Million |
Income Tax Expense/Benefit | $23.32 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-184.45 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Inventory | $596.36 Million |
Equity Attributable To Noncontrolling Interest | $135000.00 |
Noncurrent Liabilities | $2.40 Billion |
Other Non-current Assets | $736.48 Million |
Accounts Payable | $235.00 Million |
Wages | $64.90 Million |
Fixed Assets | $431.02 Million |
Other Non-current Liabilities | $5.15 Million |
Other Current Assets | $916.93 Million |
Intangible Assets | $780.19 Million |
Assets | $3.46 Billion |
Current Assets | $1.51 Billion |
Liabilities And Equity | $3.46 Billion |
Long-term Debt | $2.39 Billion |
Equity | $-93.57 Million |
Noncurrent Assets | $1.95 Billion |
Equity Attributable To Parent | $-93.43 Million |
Current Liabilities | $1.10 Billion |
Other Current Liabilities | $795.31 Million |
Temporary Equity | $59.89 Million |
Liabilities | $3.49 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.